Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Robatumumab PET Activity in Colorectal Cancer
NCT00551213Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2007
- Primary completion
- Jun 2009
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, randomised, open-label trial of robatumumab in colorectal cancer (CRC) (2 arms), sponsored by Merck & Co. Primary endpoint: Number of Participants With a >20% Decrease in Positron Emission Tomography (PET)-Assessed Tumor Glucose Metabolism at 4 weeks. Started Nov 2007; status: completed.
02
Drugs
robatumumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00551213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00551213.